EverHint Lens - Apellis Pharmaceuticals, Inc. ($APLS) - Yahoo Top Gainer Stock (+135%) Analysis - March 31, 2026

Analysis Date: 2026-03-31
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ

Executive Summary

Apellis Pharmaceuticals, Inc. is currently trading at $40.29 (🟢 +135.73% today) with a market capitalization of $5.15B.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases.

Price & Valuation

Current Price: $40.29 (at 11:55 AM ET)
Current Volume: 59.1M
Day Range: $40.25 - $40.45
52-Week Range: $16.10 - $40.45
P/E Ratio: 226.77

DCF Valuation: Not applicable (negative intrinsic value)
DCF model (unlevered) calculated as of 2026-03-31.

Market Context

Major Indices:

• S&P 500: $6428.72 (🟢 +1.34%)
• NASDAQ Composite: $21172.75 (🟢 +1.82%)
• Dow Jones Industrial Average: $45666.98 (🟢 +1.00%)

Peer Comparison

Peer comparison (11 companies):

• APLS - Apellis Pharmaceuticals, Inc. ($40.29, +135.7%, $5.15B) ← Current
• CDTX - Cidara Therapeutics, Inc. ($221.38, 0.0%, $5.61B)
• SRRK - Scholar Rock Holding Corporation ($48.17, +11.8%, $5.53B)
• KNSA - Kiniksa Pharmaceuticals, Ltd. ($47.81, +4.6%, $3.55B)
• CPRX - Catalyst Pharmaceuticals, Inc. ($24.27, +2.1%, $2.98B)
• IDYA - IDEAYA Biosciences, Inc. ($32.98, +4.8%, $2.90B)
• BEAM - Beam Therapeutics Inc. ($23.26, +6.2%, $2.37B)
• AGIO - Agios Pharmaceuticals, Inc. ($36.06, +21.8%, $2.11B)
• ADPT - Adaptive Biotechnologies Corporation ($13.36, +4.0%, $2.06B)
• MLYS - Mineralys Therapeutics, Inc. ($27.17, +15.6%, $1.80B)
• RXRX - Recursion Pharmaceuticals, Inc. ($2.97, +4.7%, $1.33B)

Financial Performance

Latest Quarter (2025-12-31):

• Revenue: $199.91M
• Net Income: $-58.95M
• EPS: $-0.47
• Revenue Growth (QoQ): -56.4%

Earnings Calendar

Next Earnings Report: 2026-05-06 (Before Market Open)

• EPS Estimate: $-0.38
• Revenue Estimate: $0.20B

Most Recent Report: 2026-02-24

• EPS: $-0.47 (Est: $-0.39) ✗ Miss
• Revenue: $0.20B

Historical Data: 49 earnings events tracked

Analyst Outlook

Analyst Price Target Consensus:

• Target: $33.50 (-16.8% upside)
• Range: $19.00 - $52.00
• Median: $30.50

Next Quarter Estimates (2028-09-30):

• Revenue: $524.83M
• EPS: $1.53

Analyst Consensus

Overall Rating: Buy

Rating Distribution (289 total ratings):

• 🟢 Buy/Outperform: 214 (74.0%)
• ⚪ Hold/Neutral: 63 (21.8%)
• 🔴 Sell/Underperform: 3 (1.0%)

Recent Analyst Actions:

• Bank of America Securities (2026-01-21): Upgrade Buy → Buy
• Wolfe Research (2025-11-05): Initiate Peer Perform
• Wells Fargo (2025-10-15): Upgrade Sector Perform → Overweight
• Goldman Sachs (2025-09-26): Downgrade Buy → Sell
• Goldman Sachs (2026-01-12): Maintain Sell

Consensus based on 289 analyst ratings from major financial institutions

Trading Signals

Our technical analysis identified 2 trading signal(s) in the last 60 days:

• 2026-02-19: Ema10 Price Macd - EMA10_Price_MACD_Buy @ $22.80
• 2026-01-30: Sma20 Sma50 - SMA20_x_SMA50_Sell @ $22.58

Insider Activity

Recent Transactions (Last 10):

• Buys: 6
• Sells: 3

Notable Transactions:

• 2026-03-11: Francois Cedric - Sell (Gift, 64,869 shares)
• 2026-03-11: Francois Cedric - Buy (Gift, 64,869 shares)
• 2026-02-27: Dolsten Mikael - Buy (Award, 24,135 shares @ $20.96)

News Sentiment Analysis

AI Analysis (based on 30 recent articles):

Recent headlines are dominated by Biogen's $5.6 billion acquisition of Apellis Pharmaceuticals, causing the stock to more than double and expanding its immunology portfolio. Earlier reports show mixed Q4 earnings with revenue beats but wider losses, alongside insider selling and stock declines post-earnings. A minor shareholder investigation into the deal's fairness exists, but the acquisition drives overwhelmingly positive sentiment.

Key Themes:

• Biogen acquisition
• Stock price surge
• Mixed earnings and insider activity

Sentiment: Positive (95% confidence)

Reddit Sentiment

Community Discussion (last 30 days from r/wallstreetbets, r/stocks, r/investing):

Overall Sentiment: Strongly Bearish 📉📉 (Score: -0.557)

Post Analysis:

• Total posts: 1
• Bullish: 0 (0.0%)
• Bearish: 1 (100.0%)
• Neutral: 0 (0.0%)
• Total engagement: 8 (upvotes + comments)

Note: Sentiment score ranges from -1.0 (very bearish) to +1.0 (very bullish), weighted by post engagement.

Recent News

5 most recent articles covering APLS:

• Why This Pharma Stock More Than Doubled Today (barrons.com, 2026-03-31) — Read more
• APLS Stock Alert: Halper Sadeh LLC is Investigating Whether Apellis Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders (businesswire.com, 2026-03-31) — Read more
• Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion (wsj.com, 2026-03-31) — Read more
• Biogen to buy Apellis Pharmaceuticals for $5.6 billion (reuters.com, 2026-03-31) — Read more
• Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology (globenewswire.com, 2026-03-31) — Read more

Full news analysis based on 30 recent articles

Generated by Everhint Lens - Quantitative Stock Analysis
Last updated: 2026-03-31 08:55:50 AM PDT

Disclaimer: This is not investment advice. Always do your own research before making investment decisions.